Citation: | Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. DOI: 10.12290/xhyxzz.2022-0089 |
[1] |
Ludwig BS, Kessler H, Kossatz S, et al. RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field[J]. Cancers (Basel), 2021, 13: 1711. DOI: 10.3390/cancers13071711
|
[2] |
Kossatz S, Beer AJ, Notni J. It's time to shift the paradigm: translation and clinical application of non-alphavbeta3 integrin targeting radiopharmaceuticals[J]. Cancers (Basel), 2021, 13: 5958. DOI: 10.3390/cancers13235958
|
[3] |
Steiger K, Quigley NG, Groll T, et al. There is a world beyond alphavbeta3-integrin: multimeric ligands for imaging of the integrin subtypes alphavbeta6, alphavbeta8, alphav-beta3, and alpha5beta1 by positron emission tomography[J]. EJNMMI Res, 2021, 11: 106. DOI: 10.1186/s13550-021-00842-2
|
[4] |
Ebenhan T, Kleynhans J, Zeevaart JR, et al. Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 1414-1433. DOI: 10.1007/s00259-020-04975-9
|
[5] |
Chen H, Niu G, Wu H, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin alphavbeta3[J]. Theranostics, 2016, 6: 78-92. DOI: 10.7150/thno.13242
|
[6] |
Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study[J]. J Nucl Med, 2012, 53: 716-722. DOI: 10.2967/jnumed.111.098988
|
[7] |
Fu J, Xie Y, Fu T, et al. [(99m)Tc]Tc-Galacto-RGD(2) integrin alpha(v)beta(3)-targeted imaging as a surrogate for molecular phenotyping in lung cancer: real-world data[J]. EJNMMI Res, 2021, 11: 59. DOI: 10.1186/s13550-021-00801-x
|
[8] |
Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging[J]. J Nucl Cardiol, 2010, 17: 1065-1072. DOI: 10.1007/s12350-010-9268-5
|
[9] |
Mi B, Yu C, Pan D, et al. Pilot prospective evaluation of (18)F-Alfatide Ⅱ for detection of skeletal metastases[J]. Theranostics, 2015, 5: 1115-1121. DOI: 10.7150/thno.12938
|
[10] |
Dong Y, Wei Y, Chen G, et al. Relationship between clinicopathological characteristics and PET/CT uptake in esophageal squamous cell carcinoma: [(18)F]Alfatide versus[(18)F]FDG[J]. Mol Imaging Biol, 2019, 21: 175-182. DOI: 10.1007/s11307-018-1216-9
|
[11] |
Zheng K, Liang N, Zhang J, et al. 68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer[J]. J Nucl Med, 2015, 56: 1823-1827. DOI: 10.2967/jnumed.115.160648
|
[12] |
Kim YI, Phi JH, Paeng JC, et al. In vivo evaluation of angiogenic activity and its correlation with efficacy of indirect revascularization surgery in pediatric moyamoya disease[J]. J Nucl Med, 2014, 55: 1467-1472. DOI: 10.2967/jnumed.114.142430
|
[13] |
Iagaru A, Mosci C, Mittra E, et al. Glioblastoma multiforme recurrence: an exploratory study of (18)F-FPPRGD2 PET/CT[J]. Radiology, 2015, 277: 497-506. DOI: 10.1148/radiol.2015141550
|
[14] |
Chen SH, Wang HM, Lin CY, et al. RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 1621-1629. DOI: 10.1007/s00259-016-3345-1
|
[15] |
Beer AJ, Pelisek J, Heider P, et al. PET/CT imaging of integrin αVβ3 expression in human carotid atherosclerosis[J]. JACC Cardiovasc Imaging, 2014, 7: 178-187. DOI: 10.1016/j.jcmg.2013.12.003
|
[16] |
Roesch S, Lindner T, Sauter M, et al. Comparison of the RGD motif-containing αVβ6 integrin-binding peptides SFLAP3 and SFITGv6 for diagnostic application in HNSCC[J]. J Nucl Med, 2018, 59: 1679-1685. DOI: 10.2967/jnumed.118.210013
|
[17] |
Feng X, Wang Y, Lu D, et al. Clinical translation of a (68)Ga-labeled integrinalpha(v)beta(6)-targeting cyclic radiotracer for PET imaging of pancreatic cancer[J]. J Nucl Med, 2020, 61: 1461-1467. DOI: 10.2967/jnumed.119.237347
|
[18] |
Quigley NG, Steiger K, Hoberück S, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" alphavbeta6 with Ga-68-Trivehexin[J]. Eur J Nucl Med Mol Imaging, 2021, 24: 1-12.
|
[19] |
Kimura RH, Wang L, Shen B, et al. Evaluation of integrin alpha v beta(6) cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis[J]. Nat Commun, 2019, 10: 4673. DOI: 10.1038/s41467-019-11863-w
|
[20] |
Hausner SH, Bold RJ, Cheuy LY, et al. Preclinical development and first-in-human imaging of the integrin alphavbeta6 with[18F]alphavbeta6-binding peptide in metastatic carcinoma[J]. Clin Cancer Res, 2019, 25, 1206-1215.
|
[21] |
Sharma R, Valls PO, Inglese M, et al. [(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 1239-1251. DOI: 10.1007/s00259-019-04532-z
|
[22] |
Zheng Y, Wang H, Tan H, et al. Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin αVβ3[J]. Clin Nucl Med, 2019, 44: 687-694. DOI: 10.1097/RLU.0000000000002680
|
[23] |
Zhang J, Mao F, Niu G, et al. (68)Ga-BBN-RGD PET/CT for GRPR and integrin alphavbeta3 imaging in patients with breast cancer[J]. Theranostics, 2018, 8: 1121-1130. DOI: 10.7150/thno.22601
|
[24] |
Liolios C, Sachpekidis C, Kolocouris A, et al. PET diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin alpha(v)beta(3) receptors[J]. Molecules, 2021, 26: 1792. DOI: 10.3390/molecules26061792
|
[25] |
Wu Z, Li ZB, Cai W, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression[J]. Eur J Nucl Med Mol Imaging, 2007, 34: 1823-1831. DOI: 10.1007/s00259-007-0427-0
|
[26] |
Chen H, Jacobson O, Niu G, et al. Novel "add-On" molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostics agents[J]. J Nucl Med, 2017, 58: 590-597. DOI: 10.2967/jnumed.116.182097
|
[27] |
Li D, Zhao X, Zhang L, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study[J]. Mol Pharm, 2014, 11: 3923-3929. DOI: 10.1021/mp5003224
|
[28] |
Kang F, Wang Z, Li G, et al. Inter-heterogeneity and intra-heterogeneity of alpha(v)beta(3) in non-small cell lung cancer and small cell lung cancer patients as revealed by (68)Ga-RGD(2) PET imaging[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1520-1528. DOI: 10.1007/s00259-017-3696-2
|
[29] |
Tonnelet D, Bohn MDP, Becker S, et al. Angiogenesis imaging study using interim[(18)F]RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence[J]. EJNMMI Res, 2021, 11: 37. DOI: 10.1186/s13550-021-00776-9
|
[30] |
Jin X, Liang N, Wang M, et al. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer[J]. Radiology, 2016, 281: 958-966. DOI: 10.1148/radiol.2016150813
|
[31] |
Miao W, Zheng S, Dai H, et al. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: A multicenter study[J]. PLoS One, 2014, 9: e111221. DOI: 10.1371/journal.pone.0111221
|
[32] |
Li L, Ma L, Shang D, et al. Pretreatment PET/CT imaging of angiogenesis based on (18)F-RGD tracer uptake may predict antiangiogenic response[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 940-947. DOI: 10.1007/s00259-018-4143-8
|
[33] |
Sun Y, Zeng Y, Zhu Y, et al. Application of (68)Ga-PRGD2 PET/CT for αVβ3-integrin imaging of myocardial infarction and stroke[J]. Theranostics, 2014, 4: 778-786. DOI: 10.7150/thno.8809
|
[34] |
Luo Y, Sun Y, Zhu Z, et al. Is the change of integrin α(v)β(3) expression in the infarcted myocardium related to the clinical outcome?[J]. Clin Nucl Med, 2014, 39: 655-657. DOI: 10.1097/RLU.0000000000000426
|
[35] |
Lobeek D, Bouwman FCM, Aarntzen EHJG, et al. A clinical feasibility study to image angiogenesis in patients with arteriovenous malformations using (68)Ga-RGD PET/CT[J]. J Nucl Med, 2020, 61: 270-275. DOI: 10.2967/jnumed.119.231167
|
[36] |
Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study[J]. Ann Rheum Dis, 2014, 73: 1269-1272. DOI: 10.1136/annrheumdis-2013-204820
|
[37] |
Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin alphavbeta6 by[(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 967-979. DOI: 10.1007/s00259-019-04586-z
|
[1] | ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605 |
[2] | QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023 |
[3] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
[4] | Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. DOI: 10.12290/xhyxzz.2022-0584 |
[5] | KONG Linghua, XIAO Xiaoping, WAN Ru, XIANG Yang. Clinical Application of ThinPrep Imaging System in Cervical Cytology[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 613-619. DOI: 10.12290/xhyxzz.2022-0221 |
[6] | ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180 |
[7] | Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555 |
[8] | Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology. Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 189-201. DOI: 10.12290/xhyxzz.2021-0082 |
[9] | Noyes' Knee Disorders: Surgery, Rehabilitation, Clinical Outcomes(2nd ed.)(2016)[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(1): 18-18. |
[10] | MAIMAITI Nu-rong-gu-li, Hua-bing ZHANG, Xiao-ping XING. Clinical and Genetic Analysis of a Uyghur Patient with Gitelman's Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 427-431. DOI: 10.3969/j.issn.1674-9081.2015.06.006 |
1. |
刘玉文,张丽梅,王永丽,徐小梅,母亚丹,杨志杰,杨树婷,罗凤云. 老年多学科团队服务对共病伴营养不良老年患者的疗效分析. 昆明医科大学学报. 2024(12): 81-87 .
![]() |